Volume : 13, Issue : 01, January – 2026

Title:

MICROSPHERE-BASED DELIVERY OF DABIGATRAN: ADVANCES IN CONTROLLED RELEASE ANTICOAGULANT THERAPY

Authors :

Hemendra Nandkishor Khatri*, Ashish Wagh, Dr. Vaishali Rathi

Abstract :

Dabigatran etexilate, a direct thrombin inhibitor, has emerged as a valuable oral anticoagulant for the prevention and treatment of thromboembolic disorders. Despite its clinical utility, conventional formulations of dabigatran are limited by low oral bioavailability, dependence on intestinal transporters, and variability in patient response. These challenges have stimulated interest in advanced drug delivery systems, particularly microsphere-based formulations, to optimize therapeutic outcomes.
Microspheres, prepared using techniques such as ionic gelation, emulsion coacervation, solvent evaporation, and spray drying, encapsulate dabigatran within biodegradable polymers including chitosan, Eudragit RL100, and PLGA. Such systems offer controlled and sustained drug release, enhanced gastrointestinal stability, and improved absorption, thereby addressing the pharmacokinetic shortcomings of conventional tablets. By maintaining steady plasma concentrations and reducing peak–trough fluctuations, microsphere formulations improve pharmacodynamic predictability, minimize bleeding risks, and enhance patient compliance through reduced dosing frequency.
This review highlights the formulation strategies, polymeric approaches, and pharmacokinetic improvements achieved with dabigatran microspheres, while also discussing their translational potential and future directions. Microsphere-based delivery represents a promising advancement in controlled release anticoagulant therapy, with the potential to transform clinical practice by offering safer, more effective, and patient-friendly treatment options.
KEYWORDS: Dabigatran etexilate, Microspheres, Controlled release drug delivery, anticoagulants, Bioavailability, Thrombin

Cite This Article:

Please cite this article in press Hemendra Nandkishor Khatri et al., Microsphere-Based Delivery Of Dabigatran: Advances In Controlled Release Anticoagulant Therapy , Indo Am. J. P. Sci, 2026; 13(01).

REFERENCES:

1. Palta, S.; Saroa, R.; Palta, A. Overview of the coagulation system. Indian J. Anaesth. 2014, 58, 515–523.
2. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J.; et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009, 361, 1139–1151.
3. J. Lee, R. Patel, Wastewater treatment by polymeric microspheres: a review. Polymers (2022).
4. Ogunjimi AT, Fiegel J, Brogden NK. Design and characterization of spray-dried chitosan-naltrexone microspheres for microneedle-assisted transdermal delivery. Pharmaceutics. 2020;12(6):496.
5. Bonany M, Del-Mazo-Barbara L, Espanol M, Ginebra MP. Microsphere incorporation as a strategy to tune the biological performance of bioinks. J Tissue Eng. 2022;13:20417314221119895.
6. Xiao Q, Ji Y, Xiao Z, Zhang Y, Lin H, Wang Q. Novel multifunctional NaYF₄:Er³⁺,Yb³⁺/PEGDA hybrid microspheres: NIR-light-activated photo-polymerization and drug delivery. Chem Commun (Camb). 2013;49(15):1527–1529.
7. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent Extraction/ Evaporation: reviewing the state of the art of microsphere preparation process technology. J Controlled Release 2004;102:313–32.
8. Sahil K, Akanksha M, Premjeet S, Bilandi A, Kapoor B, Microsphere: a review. Int J Res Pharm Chem 2011;1:2231-781.
9. Kavita Kunchu, Raje Veera Ashwani et al. Albumin Microspheres: A Unique system as drug delivery carriers for non steroidal antiinflammatory drugs. 2010;5(2):12.
10. Saralidze K., Koole L.H., Knetsch M. L. W. Polymeric microspheres for medical applications, Materials. 2010;3:3537-64.
11. Kappor D, Patel M, Vyas RB, Lad C, Tyagi BL, A review on microsponge drug delivary system, Journal of drug delivery and therapeutics, 2014:4(5):29-35.
12. Wieland-Berghausen, S.; Schote, U.; Frey, M.; Schmidt, F. Comparison of microencapsulation techniques for the water-soluble drugs nitenpyram and clomipramine HCl. J. Controlled Release 2002, 85 (1), 35–43.
13. van Ryn J., Hauel N., Waldmann L., Wienen W. Dabigatran inhibits both clot-bound and fluid phase thrombin in vitro: effects compared to heparin and hirudin [abstract no. 3998]. Blood (ASH Annual Meeting Abstracts) 2007 Nov 16; 110 (11).
14. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.
15. Eriksson BI, Dahl OE, Buller HR, et al, for the BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103-111.
16. N. Somani, K.S. Rathore, Formulation and evaluation of mucoadhesive chitosan microspheres of carvedilol for nasal administration. IP Int. J. Comp. Adv. Pharm. (2023).
17. A. Kumar, Microspheres: a review. Pharm. Pharm. Sci. World J (2017).
18. u Y, Zhang B, Sun R, Liu W, Zhu Q, Zhang X, Wang R, Chen C. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv. 2021 Dec;28(1):1397-1418.
19. Microfluidic preparation of monodisperse PLGA-PEG/PLGA microspheres with controllable morphology for drug release. Lab Chip. 2024 Sep 24;24(19):4623-4631.
20. Oh JE, Nam YS, Lee KH, Park TG. Conjugation of drug to poly(D,L-lactic-co-glycolic acid) for controlled release from biodegradable microspheres. J Control Release. 1999 Feb 22;57(3):269-80.
21. A.N. Yawalkar, M.A. Pawar, P.R. Vavia, Microspheres for targeted drug delivery-a review on recent applications. J. Drug Delivery Sci. Technol. 75, 103659 (2022).
22. Härtter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, Reilly PA. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012 Sep;74(3):490-500.
23. Kaurav H, Hari Kumar SL, Kaur A. Mucoadhesive microspheres as carriers in drug delivery: a review. Int. j drug dev research. 2012:21-34.
24. Pranali Adsul, 2Ajay Shinde and 3 Suvarna Sonawane “overview: formulation aspect of mucoadhesive microsphere and its pharmaceutical application” 2022, 9(4), 463-471.
25. Eisert WG, Hauel N, Stangier J, et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30(10):1885–1889.
26. Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet. 2016;55(6):641–655.
27. Shanthi N.C., Dr.Gupta R., Mahato K.A., Traditional and Emerging Applications of Microspheres: A Review, International Journal of Pharm Tech Research. 2010; 2(1):675-681.
28. P. Hyma and B.Jyotsna. Formulation and evaluation of gastroretentive floating microspheres of acyclovir. J. Global Trends Pharm Sci, 2020; 11 (4): 8521 – 8528.